TwinBeech Capital’s Beam Therapeutics BEAM Stock Holding History

TwinBeech Capital’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$508K	Buy	14,800 +1,540	+12%	+$46.5K	0.09%	230
2026 Q1	$316K	Buy	+13,260	New	+$368K	0.03%	443
2025 Q3	–	Sell	-47,836	Closed	-$814K	–	574
2025 Q2	$814K	Sell	47,836 -191,077	-80%	-$3.33M	0.02%	441
2025 Q1	$4.67M	Buy	238,913 +111,249	+87%	+$2.91M	0.08%	263
2024 Q4	$3.17M	Buy	127,664 +69,456	+119%	+$1.77M	0.05%	285
2024 Q3	$1.43M	Buy	+58,208	New	+$1.5M	0.03%	454
2024 Q2	–	Sell	-34,641	Closed	-$1.14M	–	536
2024 Q1	$1.14M	Buy	+34,641	New	+$1.08M	0.02%	403
2023 Q3	–	Sell	-12,846	Closed	-$410K	–	640
2023 Q2	$410K	Sell	12,846 -114,933	-90%	-$3.73M	0.01%	522
2023 Q1	$3.91M	Buy	+127,779	New	+$5.04M	0.08%	275
2022 Q4	–	Sell	-50,216	Closed	-$2.39M	–	697
2022 Q3	$2.39M	Buy	+50,216	New	+$2.86M	0.06%	307

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

TwinBeech Capital's BEAM Position: Q2 2026 in Review

TwinBeech Capital increased its Beam Therapeutics (BEAM) stake by 12% in Q2 2026, buying an estimated $46.5K and bringing the position to 14,800 shares worth $508K. The position accounts for 0.09% of the portfolio, ranked #230.

TwinBeech Capital first reported a position in BEAM in Q3 2022 and has held it in 10 quarters since. The position peaked at $4.67M in Q1 2025. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

TwinBeech Capital held 14,800 shares of Beam Therapeutics worth $508K as of Q2 2026.
TwinBeech Capital bought 1,540 Beam Therapeutics shares in Q2 2026, an estimated $46.5K.
Beam Therapeutics made up 0.09% of TwinBeech Capital's portfolio in Q2 2026, its #230 holding.
TwinBeech Capital first reported a position in Beam Therapeutics in Q3 2022 and has held it in 10 quarters since.
TwinBeech Capital's Beam Therapeutics position peaked at $4.67M in Q1 2025.
277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on TwinBeech Capital's 13F filing for Q2 2026, filed 14 Aug 2026.